Related MeSH Hierarchy (6)
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Blood Protein Disorders » Paraproteinemias » Waldenstrom Macroglobulinemia
Diseases [C] » Cardiovascular Diseases [C14] » Vascular Diseases » Hemostatic Disorders » Waldenstrom Macroglobulinemia
Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Plasma Cell » Waldenstrom Macroglobulinemia
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Hemorrhagic Disorders » Hemostatic Disorders » Waldenstrom Macroglobulinemia
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphoproliferative Disorders » Waldenstrom Macroglobulinemia
Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Paraproteinemias » Waldenstrom Macroglobulinemia
Description
A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity. MeSH
Hierarchy View
Approved Indicated Drugs (2)
Phase 4 Indicated Drugs (4)
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (21)
Centre Hospitalier Schaffner France
French Innovative Leukemia Organisation
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
Polish Lymphoma Research Group
Organization Involved with Phase 2 Indications (117)
Academic and Community Cancer Research United
Aristotle University of Thessaloniki
Beijing InnoCare Pharma Tech Co., Ltd.
Case Western Reserve University
Eastern Cooperative Oncology Group
Fondazione Italiana Diabete Onlus
Gemeinschaftspraxis Porowski & Koniczek, Heilbronn, Germany
Hoosier Cancer Research Network
Oregon Health and Science University
Sparrow Regional Cancer Center
State University of New York, Buffalo
The Wayne D. Kuni and Joan E. Kuni Foundation
Organization Involved with Phase 1 Indications (30)
Cancer and Leukemia Group B (CALGB)
City of Hope National Medical Center
Organization Involved with Other Experimental Indications (1)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
